Novel methoxybenzamide compounds for use in mch receptor related disorders
CA 2482341 A1 · Owner: Norregaard, Pia Karina · Inventors: Receveur, Jean-Marie; Hoegberg, Thomas; Elling, Christian E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel compounds of Formula (I) which modulate MCH activity are disclosed in , which A is a linker; Ar1 is an aryl or heteroaryl group; R1 is a lower alkoxy group; R2 is an R1 group or hydrogen, an OH or an NH2 group Q together with , the carbonyl forms an amide group which is further substituted with an amine group; R5 is selected from hydrogen, halogen atoms alkoxy groups, hydroxy, alkylamino groups dialkylamino groups, hydroxylalkyl groups carboxamido , groups, acylamido groups acyl groups, -CHO, nitrile, alkyl, alkenyl or alkynyl groups, -SCH3, partially or fully fluorinated alkyl alkoxy or , thioalkoxy groups such as -CH2CF3 -CF2CF3, -CF3, -OCF3, -SCF3; -SO2NH2, - SO2NHAlk, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 8, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 8, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 8, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.